1 Sagoe D, Molde H, Andreassen CS, Torsheim T, Pallesen S. The global epidemiology of anabolic-androgenic steroid use: a meta-analysis and meta-regression analysis. Ann Epidemiol. Mai 2014;24(5):383–98.
2 Brennan R, Wells JSG, Van Hout MC. The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review. Health Soc Care Community. 2017;25(5):1459–531.
3 Kanayama G, Hudson JI, Pope HG. Anabolic-Androgenic Steroid Use and Body Image in Men: A Growing Concern for Clinicians. Psychother Psychosom. 2020;89(2):65–73.
4 Kanayama G, Pope HG, Hudson JI. «Body image» drugs: A growing psychosomatic problem. Psychother Psychosom. 2001;70(2):61–5.
5 Pope HG, Kanayama G, Athey A, Ryan E, Hudson JI, Baggish A. The lifetime prevalence of anabolic-androgenic steroid use and dependence in Americans: Current best estimates. Am J Addict. 2014;23(4):371–7.
6 Goldman AL, Pope HG, Bhasin S. The health threat posed by the hidden epidemic of anabolic steroid use and body image disorders among young men. J Clin Endocrinol Metab. 2019;104(4):1069–74.
7 Griffiths S, Murray SB, Mond JM. The stigma of anabolic steroid use. J Drug Issues. 2016;46(4):446–56.
8 Bonnecaze AK, O’Connor T, Aloi JA. Characteristics and Attitudes of Men Using Anabolic Androgenic Steroids (AAS): A Survey of 2385 Men. Am J Mens Health. 1. November 2020;14(6):1557988320966536.
9 de Ronde W, Smit DL. Anabolic androgenic steroid abuse in young males. Endocr Connect. 2020;9(4):R102–11.
10 Cohen J, Collins R, Darkes J, Gwartney D. A league of their own: demographics, motivations and patterns of use of 1,955 male adult non-medical anabolic steroid users in the United States. J Int Soc Sports Nutr. 2007;4(1):1–14.
11 Pope HG, Kanayama G, Ionescu-Pioggia M, Hudson JI. Anabolic steroid users’ attitudes towards physicians. Addict Abingdon Engl. 2004;99(9):1189–94.
12 Yu J, Hildebrandt T, Lanzieri N. Healthcare professionals’ stigmatization of men with anabolic androgenic steroid use and eating disorders. Body Image. 2015;15(C):49–53.
13 Laure P, Binsinger C, Lecerf T. General practitioners and doping in sport: attitudes and experience. Br J Sports Med. 2003;37(4):335-8-discussion 338.
14 Althobiti S, Alqurashi N, Alotaibi A, Alharthi T, Alswat K. Prevalence, Attitude, Knowledge, and Practice of Anabolic Androgenic Steroid (AAS) Use Among Gym Participants. Mater Socio Medica. 2018;30(1):49–4.
15 Christiansen AV, Vinther AS, Liokaftos D. Outline of a typology of men’s use of anabolic androgenic steroids in fitness and strength training environments*. Drugs Educ Prev Policy. 2017;24(3):295–305.
16 Begley E, Mcveigh J, Hope V. Image and Performance Enhancing Drugs 2016 National Survey Results Survey co-ordinated by. 2017.
17 Pope CG, Pope HG, Menard W, Fay C, Olivardia R, Phillips KA. Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body Image. 2005;2(4):395–400.
18 Saunders JB. Substance use and addictive disorders in DSM-5 and ICD 10 and the draft ICD 11. Curr Opin Psychiatry. 2017;30(4):227–37.
19 Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Treatment of anabolic-androgenic steroid dependence: Emerging evidence and its implications. Drug Alcohol Depend. 2010;109(1–3):6–13.
20. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG. Issues for DSM-V: Clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am J Psychiatry. 2009;166(6):642–4.
21 Pope HG, Kean J, Nash A, Kanayama G, Samuel DB, Bickel WK, u. a. A diagnostic interview module for anabolic-androgenic steroid dependence: Preliminary evidence of reliability and validity. Exp Clin Psychopharmacol. 2010;18(3):203–13.
22 Kashkin KB. Hooked on Hormones? Jama. 1989;262(22):3166.
23 Halioua R, Deutschmann M, Vetter S, Jäger M, Seifritz E, Claussen MC. Dysmorphie musculaire. Forum Med Suisse. 2019;19(0910):153–8.
24 Giannini AJ, Miller N, Kocjan DK. Treating Steroid Abuse: A Psychiatric Perspective. Clin Pediatr (Phila). 1991;30(9):538–42.
25 Petersson A, Garle M, Holmgren P, Druid H, Krantz P, Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006;81(3):241–9.
26 Börjesson A, Möller C, Hagelin A, Vicente V, Rane A, Lehtihet M, u. a. Male anabolic androgenic steroid users with personality disorders report more aggressive feelings, suicidal thoughts, and criminality. Med Lith. 2020;56(6):1–12.
27 Gårevik N, Rane A. Dual use of anabolic-androgenic steroids and narcotics in Sweden. Drug Alcohol Depend. 2010;109(1–3):144–6.
28 Hope VD, McVeigh J, Marongiu A, Evans-Brown M, Smith J, Kimergård A, u. a. Prevalence of, and risk factors for, HIV, hepatitis B and C infections among men who inject image and performance enhancing drugs: A cross-sectional study. BMJ Open. 2013;3(9).
29 Chandler, Martin, Mc Veigh J. Steroids and image enhancing drugs. Bd. 8, Centre for public health. 2013.
30 Sagoe D, McVeigh J, Bjørnebekk A, Essilfie MS, Andreassen CS, Pallesen S. Polypharmacy among anabolic-androgenic steroid users: A descriptive metasynthesis. Subst Abuse Treat Prev Policy. 2015;10(1).
31 Ip EJ, Lu DH, Barnett MJ, Tenerowicz MJ, Vo JC, Perry PJ. Psychological and physical impact of anabolic-androgenic steroid dependence. Pharmacotherapy. 2012;32(10):910–9.
32 Kanayama G, Hudson JI, Pope HG. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern? Drug Alcohol Depend. 2008;98(1–2):1–12.
33 Andrews MA, Magee CD, Combest TM, Allard RJ, Douglas KM. Physical Effects of Anabolic-androgenic Steroids in Healthy Exercising Adults: A Systematic Review and Meta-analysis. Curr Sports Med Rep. 2018;17(7):232–41.
34 Cheung AS, Grossmann M. Physiological basis behind ergogenic effects of anabolic androgens. Mol Cell Endocrinol. 2018;464:14–20.
35 Smit DL, de Ronde W. Outpatient clinic for users of anabolic androgenic steroids: an overview. Neth J Med. 2018;76(4):167.
36 Kanayama G, Kaufman MJ, Pope HG. Public health impact of androgens. Curr Opin Endocrinol Diabetes Obes. 2018;25(3):218–23.
37 Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access. BMC Public Health. 2019;19(1):1024.
38 Bates G, Van Hout MC, Teck JTW, McVeigh J. Treatments for people who use anabolic androgenic steroids: A scoping review. Harm Reduct J. 2019;16(1):1–15.
39 Corcoran JP, Longo ED. Psychological Treatment of Anabolic-Androgenic Steroid-Dependent Individuals. 1992;9:229–35.
40 Rahnema CD, Lipshultz LI, Crosnoe LE, Kovac JR, Kim ED. Anabolic steroid–induced hypogonadism: diagnosis and treatment. Fertil Steril. 2014;101(5):1271–9.
41 Althobiti S, Alqurashi N, Alotaibi A, Alharthi T, Alswat K. Prevalence, Attitude, Knowledge, and Practice of Anabolic Androgenic Steroid (AAS) Use Among Gym Participants. Mater Socio Medica. 2018;30(1):49.
42 Havnes IA, Jørstad ML, Wisløff C. Anabolic-androgenic steroid users receiving health-related information; Health problems, motivations to quit and treatment desires. Subst Abuse Treat Prev Policy. 2019;14(1):1–12.
43. Harvey O, Keen S, Parrish M, van Teijlingen E. Support for people who use Anabolic Androgenic Steroids: A Systematic Scoping Review into what they want and what they access. BMC Public Health. 2019;19(1):1024.
44 Hunt N, Ashton M, Lenton S, Mitcheson L, Nelles B. A review of the evidence-base for harm reduction approaches to drug use with contributions from : 1 Introduction 2 What is harm reduction ? Plos One. 2006;3(1):16–30.
45 Brower KJ. Anabolic steroid abuse and dependence in clinical practice. Phys Sportsmed. 2009;37(4):131–40.
46 Kuhlmann T. Qualifizierte Akutbehandlung Drogenabhängiger. Suchttherapie. 2004;5(04):6.
48 Office fédéral de la santé publique OFSP. Stratégie nationale Addictions 2017–2024. 2015;(novembre):87.